drugset / Trial / NCT00859105

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis

NCT00859105

Phase 3 Completed 497 enrolled Apotex Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Bio-equivalence Study

Timeline

Start
2008-02
Primary completion
2008-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 5 % Topical

Indications